RxDoctor Payments Data

James McGinley, MD

Internal Medicine · Franklin, TNNPI 1194716662

Payments from drug & device makers

$10,324in general payments, 2019–2025

Across 619 payments — averaging $16.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Lilly USA, LLC$925
  • AbbVie$913
  • GSK$882
  • Pfizer$785
  • AstraZeneca$643
  • plus $4K from 41 others

What the payments were for

  • Food & beverage$10,324100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$10,324 in reported general payments places this provider in the 90th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$204,524
Medicare patients
280
Services billed
6,497

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide77$73,522
EliquisApixaban66$60,633
OzempicSemaglutide46$46,231
MounjaroTirzepatide45$44,767
JanuviaSitagliptin Phosphate21$25,079
JardianceEmpagliflozin18$23,512
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$16,714
Breo ElliptaFluticasone/Vilanterol24$15,041
Lagevrio (Eua)Molnupiravir14$11,696
XareltoRivaroxaban16$11,038
LinzessLinaclotide15$8,177
MyrbetriqMirabegron15$6,623
Atorvastatin Calcium396$4,787
Candesartan Cilexetil48$4,448
Dexlansoprazole DrDexlansoprazole16$3,951

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$925$118,288122 claims
PfizerEliquis, Paxlovid$785$62,06390 claims
Novo NordiskOzempic$2,015$46,23146 claims
MerckJanuvia, Lagevrio (Eua)$386$36,77535 claims
GSKTrelegy Ellipta, Breo Ellipta$882$31,75539 claims
Boehringer IngelheimJardiance$460$23,51218 claims
Johnson & JohnsonXarelto$85$11,03816 claims
AbbVieLinzess, Synthroid$913$9,47749 claims
Astellas Pharma US IncMyrbetriq$240$6,62315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,216 internal medicine providers in Tennessee.

Other internal medicine in Franklin

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →